Paper22944331
Prediction and monitoring of treatment effect using T1-weighted dynamic contrast-enhanced magnetic resonance imaging in colorectal liver metastases: potential of whole tumour ROI and selective ROI analysis.
Coenegrachts K and 3 others. Eur J Radiol, 2012. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Prediction and monitoring of treatment effect using T1-weighted dynamic contrast-enhanced magnetic resonance imaging in colorectal liver metastases: potential of whole tumour ROI and selective ROI analysis. Papers, record 22944331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22944331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Prediction and monitoring of treatment effect using T1-weighted dynamic contrast-enhanced magnetic resonance imaging in colorectal liver metastases: potential of whole tumour ROI and selective ROI analysis.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma | Major topic |
| Colorectal Neoplasms | Major topic |
| Liver Neoplasms | Major topic |
| Magnetic Resonance Imaging | Major topic |
| Aged | |
| Aged, 80 and over | |
| Contrast Media | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Reproducibility of Results | |
| Sensitivity and Specificity | |
| Treatment Outcome |
Source PubMed
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36688023 | Role of advanced imaging techniques in the evaluation of oncological therapies in patients with colorectal liver metastases. | World J Gastroenterol | 2023 | https://conductscience.org/library/papers/36688023 | PubMed |
| 33989042 | Quantitative magnetic resonance imaging for focal liver lesions: bridging the gap between research and clinical practice. | Br J Radiol | 2021 | https://conductscience.org/library/papers/33989042 | PubMed |
| 32514496 | Evaluation of liver tumour response by imaging. | JHEP Rep | 2020 | https://conductscience.org/library/papers/32514496 | PubMed |
| 31787860 | Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI. | Contrast Media Mol Imaging | 2019 | https://conductscience.org/library/papers/31787860 | PubMed |
| 31558870 | Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging. | World J Gastroenterol | 2019 | https://conductscience.org/library/papers/31558870 | PubMed |
| 30418878 | Discontinuity Preserving Liver MR Registration with 3D Active Contour Motion Segmentation. | IEEE Trans Biomed Eng | 2018 | https://conductscience.org/library/papers/30418878 | PubMed |
| 29922934 | Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. | Eur Radiol | 2019 | https://conductscience.org/library/papers/29922934 | PubMed |
| 28977973 | Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. | Oncotarget | 2017 | https://conductscience.org/library/papers/28977973 | PubMed |
| 27187730 | Assessment of Aggressiveness of Breast Cancer Using Simultaneous 18F-FDG-PET and DCE-MRI: Preliminary Observation. | Clin Nucl Med | 2016 | https://conductscience.org/library/papers/27187730 | PubMed |
| 26911889 | Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. | Eur Radiol | 2016 | https://conductscience.org/library/papers/26911889 | PubMed |
| 26494642 | Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases. | Eur Radiol | 2016 | https://conductscience.org/library/papers/26494642 | PubMed |
| 26078555 | Prognostication and response assessment in liver and pancreatic tumors: The new imaging. | World J Gastroenterol | 2015 | https://conductscience.org/library/papers/26078555 | PubMed |
| 23836505 | Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. | Mol Imaging Biol | 2014 | https://conductscience.org/library/papers/23836505 | PubMed |
| 23732687 | Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. | Eur Radiol | 2013 | https://conductscience.org/library/papers/23732687 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22944331
GET https://conductscience.org/api/papers/v1/22944331/authors